LNs examined in situ | TBR of MFI* | ||||||||
mAb | No. of mice tested | n | Percentage DsRed-positive | Mean | SD | AUC† (%) | Sensitivity (%) | Specificity (%) | Optimal TBR cutoff for MFI |
9601 | 10 | 20 | 45 | 1.48 | 0.4 | 87.0‡ | 88.9 | 63.6 | 1.09 |
153 | 9 | 33 | 48 | 3.45§ | 1.8 | 58.0 | 81.3 | 35.3 | 1.97 |
7 | 10 | 29 | 38 | 5.24§ | 0.8 | 96.0‡ | 100.0 | 88.9 | 4.06 |
69 | 15 | 46 | 26 | 1.58 | 0.1 | 18.9 | 33.3 | 23.5 | Not applicable∥ |
↵* Mean TBR (±SD) of MFI for DsRed-positive lymph nodes in prostate cancer–positive mice.
↵† AUC from ROC curve analysis.
↵‡ P < 0.001 and < 0.006 for mAbs 7 and 9601, respectively, vs. AUC of 50% (line of nondiscrimination).
↵§ P < 0.05 for mAbs 7 and 153 vs. mAb 69 and mAb 9601 and for mAb 7 vs. mAb 153.
↵∥ Not applicable because mAb 69 is isotype control.